What is muscle dysmorphia?
Muscle dysmorphia is a clinically significant preoccupation with the belief that one's body is insufficiently muscular, large, or lean, accompanied by repetitive appearance-related behaviors and substantial distress or impairment. The central problem is the person's relationship to perceived muscular inadequacy. A person may possess considerable muscle mass and still experience their physique as unacceptable. The clinical pattern can involve long hours of rumination, checking or concealment, rigid training and food rules, avoidance of social situations, and the sacrificing of relationships, health, or work to the pursuit of a particular physique. Under DSM-5-TR, muscle dysmorphia is a specifier of body dysmorphic disorder (BDD), within the obsessive-compulsive and related disorders grouping. Its assessment therefore requires the full BDD diagnostic framework, rather than a judgment based on muscularity or gym attendance. Nagata et al. (2026) and American Psychiatric Association diagnostic criteria provide clinical starting points.
Muscle dysmorphia is sometimes called bigorexia or reverse anorexia in popular language. Those labels describe aspects of the experience but are not the formal DSM-5-TR diagnosis. The condition is best understood as an appearance-focused disturbance involving cognition, emotion, behavior, and social functioning. Resistance training, athletic ambition, attention to nutrition, and enjoyment of muscular aesthetics are common human activities; clinical concern arises when preoccupation becomes persistent, repetitive responses become difficult to control, and meaningful functioning or safety is affected.
Clinical classification and diagnostic boundaries
The BDD framework and muscularity specifier
A BDD assessment examines four central questions. First, is the person preoccupied with one or more perceived defects in appearance that other people do not observe or consider slight? Second, has the person performed repetitive behaviors, such as checking, comparison, grooming, or reassurance seeking, or repetitive mental acts in response to the concern? Third, does the preoccupation cause clinically significant distress or impairment in social, occupational, educational, or other important functioning? Fourth, is the appearance preoccupation better explained by concerns with body fat or weight in someone whose presentation meets criteria for an eating disorder? The muscle dysmorphia specifier applies when the individual is preoccupied with the idea that their body build is too small or insufficiently muscular, even if other appearance concerns are also present. A clinician assesses all elements and relevant alternatives, including insight and comorbid conditions. DSM-5-TR-related BDD criteria; Nagata et al. (2026).
The degree of conviction varies. Some individuals recognize that their judgment of their physique may be exaggerated; others are nearly or fully convinced that their body is inadequately developed despite evidence to the contrary. BDD has clinical insight specifiers, including absent insight or delusional beliefs. Strong conviction alone does not automatically change a BDD presentation into a primary psychotic disorder. Assessment must establish the overall pattern of symptoms and any additional psychotic features. This is particularly important when the patient experiences intense shame or has avoided disclosing the full extent of their concerns. American Psychiatric Association, DSM-5-TR text updates.
What makes muscularity concern clinically significant?
The question is how the pursuit operates in daily life. Someone may train regularly, track protein intake, enter bodybuilding competitions, or pursue a strength goal without BDD. More concerning patterns include repeated distress after seeing one's reflection, inability to miss an exercise session even when injured, extreme disruption when planned meals change, persistent concealment of a muscular body as supposedly inadequate, avoidance of intimacy because of anticipated appearance judgments, and rigid rules that repeatedly override personal commitments. No individual behavior establishes a diagnosis in isolation. Frequency, subjective control, distress, impairment, and medical risk determine clinical significance.
Muscle dysmorphia and general body dissatisfaction may coexist, but they differ in scope and clinical threshold. Body dissatisfaction describes an unfavorable appraisal of appearance; it is a broad psychological construct present at many intensities. Muscle dysmorphia identifies a particular BDD presentation with a muscularity-related preoccupation, repetitive acts, and impairment. The comparison matters because an educational body-image intervention is not equivalent to treatment for a diagnosed BDD syndrome. NICE BDD guidance.
Symptoms and lived experience
Appearance-related thoughts and emotions
The cognitive core often consists of repeated judgments such as being too small, insufficiently defined, or physically inadequate. Attention may narrow to certain muscle groups or perceived proportions, and the individual may interpret ordinary variations in lighting, posture, or temporary muscle fullness as evidence of an unacceptable body. Others' reassurance may produce a brief reduction in distress without changing the underlying belief. Emotional consequences can include anxiety before social events, shame when exposed to mirrors or photographs, irritability when training plans are disrupted, and low mood when progress is felt to be inadequate. These experiences can fluctuate within a single day, so a brief interview that asks only about satisfaction with appearance can miss the repetitive and situational character of symptoms.
Some people experience strong pride in athletic achievement while simultaneously feeling inadequate about their appearance. Their motivation and distress can coexist. Research describes associations with perfectionism, appearance comparison, and social physique anxiety, but these correlates do not prove a single causal pathway. The systematic review by Mitchell et al. (2017) found that higher muscle dysmorphia symptoms co-occurred with multiple psychological difficulties across weight-training samples; much of the underlying evidence was cross-sectional and methodologically variable.
Checking, avoidance, reassurance, and concealment
Common repetitive acts include measuring arms or chest, inspecting the body in mirrors, taking and reviewing photographs, repeatedly comparing one's physique with other people, checking weight or body composition, and seeking confirmation of muscularity. People can also avoid mirrors, locker rooms, swimming, fitted clothing, photographs, or intimacy. Checking and avoidance may occur in the same person across different situations. These behaviors can reinforce the preoccupation when they temporarily relieve uncertainty or prevent the person from discovering that feared judgments are less likely or less consequential than anticipated.
A practitioner should ask what happens before and after these behaviors. Is the mirror used for ordinary grooming or to neutralize intense anxiety? Does checking stop after obtaining practical information, or resume because certainty remains elusive? Does social avoidance protect against a specific feared humiliation? Behavioral function provides more diagnostic information than merely counting workouts or photographs. This formulation draws on established BDD cognitive-behavioral treatment principles. NICE CG31.
Training, food rules, and functional impairment
Training can be a valued activity while becoming increasingly compulsory. A person may extend sessions despite pain, feel unable to take recovery days, or organize nearly all daily activity around workouts. Food patterns may become highly prescriptive, with distress following ordinary changes in meal timing or composition. These patterns may involve adequate or inadequate nutrition; a diagnosis cannot be inferred from the kind of diet alone. Clinicians should assess medical consequences, flexibility, relationships, school or work, sleep, and the ability to participate in other valued activities.
Impairment may appear before physical harm is obvious. A person might decline a family event because it conflicts with a workout, withdraw from a partner because of body shame, or become unable to concentrate at work due to persistent appearance rumination. Clinical assessment asks whether such losses are attributable to muscularity preoccupation, another psychiatric condition, occupational demands, sport-specific expectations, or several interacting factors. Nagata et al. (2026).
Psychological models and maintaining mechanisms
Appearance threat, selective attention, and interpretation
A cognitive-behavioral formulation describes how an appearance-related threat belief can shape attention and action. Someone who assumes that insufficient size makes them unacceptable may scan for flaws, compare themselves with carefully selected peers, and interpret small deviations from an ideal as failure. Repeated checking heightens the salience of the feared feature; avoidance prevents alternative learning; reassurance can create short-lived relief followed by further uncertainty. The loop can continue even after visible physical changes because the criteria for feeling sufficiently muscular are psychologically unstable rather than based on a fixed athletic target.
Perceptual research sometimes finds discrepancies between measured physique and perceived adequacy. Such findings should not be simplified into a claim that everyone with muscle dysmorphia literally sees an objectively smaller body. Perception, evaluative judgment, selective attention, memory, and motivational standards are distinct processes. Clinical interviews and measurement strategies should address each separately. Hildebrandt et al. (2004); Nagata et al. (2026).
Ideal internalization and social comparison
Cultural muscularity ideals, peer norms, competitive fitness settings, and appearance-centered media can provide the standards against which people evaluate their bodies. Internalization occurs when an external ideal becomes a personal criterion for worth or success. Comparisons to extremely muscular or digitally manipulated images may contribute to dissatisfaction in some circumstances. Social influence depends on exposure, preexisting concerns, comparison habits, the meaning assigned to appearance, and broader social conditions. Correlational associations do not establish that a particular platform or image causes a clinical disorder in an individual.
The social model also explains why symptom descriptions should consider race, ethnicity, culture, gender, age, disability, sexual orientation, and the demands of particular sports. A standardized muscular ideal is not universally shared. Digital images, visual enhancement, anabolic drug culture, and competitive environments change the reference group; their influence should be investigated without presuming that all athletes or fitness communities are pathological. Mitchell et al. (2017); Nagata et al. (2026).
Compulsivity, reward, and identity
The wish to build muscle can become linked to routines that serve several functions: reducing anxiety, avoiding shame, pursuing achievement, obtaining community recognition, or maintaining a valued identity. Repetitive conduct does not establish obsessive-compulsive disorder (OCD), and exercise itself should not be classified as an addiction merely because it is frequent. When compulsive training occurs alongside BDD, a clinician explores the feared consequences of deviating from the routine, the perceived necessity of the act, and how it affects functioning. The 2025 systematic review and meta-analysis by Çınaroğlu and Yılmazer reported a positive relationship between muscle dysmorphia symptom severity and obsessive-compulsive traits. The pooled estimate was approximately r = 0.24, and the underlying quantitative evidence was small and predominantly drawn from male weight-training groups. Association supports clinical assessment of related symptoms; it does not establish that muscle dysmorphia and OCD are the same disorder.
Who may experience muscle dysmorphia?
Men, women, and gender-diverse people
Muscle dysmorphia research has historically centered on men, particularly weightlifters, bodybuilders, and young adults. This sampling history influences estimates of how frequently symptoms occur and which signs are easiest to recognize. Women and gender-diverse people can also experience a muscularity-focused preoccupation, and cultural expectations may shape how it appears. The clinician should ask about each person's personally meaningful ideals rather than assume that muscularity concern implies a particular sex, gender identity, sexual orientation, or athletic identity. A 2026 measurement study in Brazilian transgender men and gender-expansive individuals supported key psychometric properties of the Muscle Dysmorphic Disorder Inventory in that sample, illustrating why direct validation matters. Almeida et al. (2026).
Adolescence and early adulthood
Adolescence brings rapid physical development, stronger social comparison in some contexts, and changing expectations about gendered appearance. Young people may encounter intensive physique advice, supplement advertising, and highly edited visual ideals before they have developed stable judgments about body composition or long-term health risks. Persistent shame, compulsive exercise, abrupt dietary restriction, steroid use, and social withdrawal warrant sensitive assessment. The age-specific literature remains limited relative to adult cross-sectional samples, and clinicians should consider pubertal stage, growth, family and school environments, and exposure to bullying. Nagata et al. (2026).
Athletes and weight-training communities
Sport participation is a context, not a diagnosis. In the review by Mitchell et al. (2017), 31 eligible studies included 5,880 participants, about 90% male. Bodybuilders tended to report higher symptoms than other resistance trainers on several instruments, yet the included studies had generally poor-to-moderate quality and could not establish whether bodybuilding increased symptoms or whether people with preexisting concerns were disproportionately drawn to the activity. Professional assessment must account for legitimate training demands while identifying distress, inflexibility, medical risk, and loss of autonomy.
Muscle dysmorphia and related conditions
Body dissatisfaction and the drive for muscularity
The drive for muscularity describes motivation to develop a muscular physique, a dimension studied in both clinical and nonclinical populations. A high drive can reflect sport goals or culturally learned ideals without reaching the threshold for BDD. Body dissatisfaction is a negative evaluation of one's body or appearance and may occur without compulsions or impairment. Muscle dysmorphia involves an appearance preoccupation, repetitive behaviors, and clinically important consequences. Screening tools often measure all three at once; clinical evaluation separates motivation, dissatisfaction, and syndrome severity. Hildebrandt et al. (2004).
Eating disorders and disordered eating
Muscularity-related food rules and body-composition goals can overlap with restrictive eating, binge eating, purging, and other eating-disorder presentations. The meaning of a behavior matters: restriction may be driven principally by fear of weight gain, by concerns about inadequate muscularity, or by several fears. The DSM-5-TR BDD criteria require assessment of whether body-fat or weight concerns are better explained by an eating disorder. A person can meet criteria for more than one condition when each has independent clinical features, and nutritional or medical instability requires attention regardless of diagnostic label. Eating disorders have their own diagnostic criteria and evidence-based treatment pathways; muscle dysmorphia should never be used to obscure those needs. DSM-related clinical criteria; Nagata et al. (2026).
Obsessive-compulsive disorder, exercise dependence, and social anxiety
OCD involves obsessions and compulsions that may center on contamination, harm, symmetry, taboo content, or other themes. Muscle dysmorphia involves a specific appearance-related preoccupation and is classified with BDD; shared compulsive mechanisms do not erase diagnostic differences. Exercise dependence or exercise addiction scales usually assess inability to regulate exercise, withdrawal-like distress, and conflict with other responsibilities. They do not, on their own, measure the appearance-related beliefs necessary to identify muscle dysmorphia. Social anxiety disorder primarily concerns feared negative evaluation in social situations; an individual with muscle dysmorphia may avoid social situations due to a particular perceived physical defect. The focus of fear, repetitive acts, broader symptom pattern, and impact of appearance beliefs help distinguish these conditions. Çınaroğlu and Yılmazer (2025); NICE clinical guidance.
Anabolic-androgenic steroid use and substance-related disorders
Some individuals with muscle dysmorphia use anabolic-androgenic steroids or other performance-enhancing drugs because their body seems perpetually inadequate. Steroid use is neither necessary nor sufficient for diagnosis, and not everyone using such substances has muscle dysmorphia. Conversely, the presence of muscle dysmorphia does not establish substance dependence. The Çınaroğlu and Yılmazer (2025) review found higher mean muscle dysmorphia symptom scores in steroid users than non-users, with a pooled standardized difference around d = 0.45. Its limited, predominantly observational evidence cannot determine whether preoccupation contributed to drug use, drug use intensified concerns, or shared factors shaped both.
Medical assessment should ask nonjudgmentally about prescribed and nonprescribed hormones, anabolic agents, stimulants, supplements, and injection practices. Risks can include cardiovascular, endocrine, reproductive, hepatic, psychiatric, and infectious complications, depending on the substance and use pattern. Assessment also distinguishes withdrawal or drug-induced symptoms from primary mood or anxiety conditions. Abrupt changes to a medical regimen or unmonitored attempts to manage withdrawal carry risks and require appropriate professional care. Nagata et al. (2026); Çınaroğlu and Yılmazer (2025).
Clinical assessment: from first conversation to diagnosis
A sensitive, function-centered clinical interview
A useful assessment begins with an open invitation: what aspects of the body feel unacceptable, how much time is spent thinking about them, what happens after looking in a mirror, and which activities have been disrupted? The clinician then asks about checking, comparison, concealment, reassurance, exercise and diet rigidity, injury, drug use, interpersonal withdrawal, and the degree of belief in perceived defects. Inquiry should address duration, distress, functional impairment, and whether symptoms fluctuate with events or contexts. It should also consider depression, OCD, social anxiety, eating disorders, trauma, self-harm, suicidal thoughts, and other relevant concerns. Respectful inquiry is important because embarrassment, athletic norms, or fear of being told to stop exercising can reduce disclosure.
Clinical assessment includes developmentally and culturally informed interpretation and may involve physicians, licensed mental health professionals, dietitians, and substance-use specialists. The need for a medical evaluation depends on nutritional status, training injuries, possible medication or steroid complications, endocrine symptoms, and other physical concerns. A diagnostic interview cannot be replaced by appearance photographs, body mass index, visible muscle size, or a gym coach's impression. Nagata et al. (2026).
Muscle Dysmorphic Disorder Inventory (MDDI)
The MDDI is a 13-item self-report instrument developed to assess symptoms related to the drive for size, appearance intolerance, and functional impairment. It is widely used in studies and provides a structured way to discuss muscularity-related difficulties. It is not a stand-alone diagnostic test. Elevated scores indicate a need to understand symptoms in clinical context, while a low score does not rule out a complex presentation. A cutoff used in one group may not be validated for another language, age, gender, or sampling context. In particular, screening thresholds reported in research should not be promoted as universal diagnostic criteria. Hildebrandt et al. (2004); Compte et al. (2025), measure overview.
Muscle Dysmorphia Inventory, drive-for-muscularity measures, and BDD scales
The Muscle Dysmorphia Inventory (MDI) is another questionnaire developed to assess characteristic attitudes and behaviors; despite similar abbreviations, it is distinct from the MDDI. Measures of drive for muscularity capture a related motivational construct and should not be treated as proof of a clinical disorder. A clinician assessing a suspected BDD presentation may also use a structured diagnostic interview and the clinician-rated Yale–Brown Obsessive Compulsive Scale modified for BDD to characterize severity and treatment response. Every scale has its intended population and psychometric limits, and cross-cultural use requires appropriate validation. Rhea, Lantz, and Cornelius (2004); Phillips et al. (1997); Hildebrandt et al. (2004).
Screening, diagnosis, severity, and monitoring
Screening estimates whether a fuller evaluation may be warranted. Diagnosis integrates clinical criteria, impairment, developmental context, differential diagnosis, comorbidity, and risk. Severity monitoring asks whether preoccupation, rituals, avoidance, functioning, and wellbeing change over time. These three tasks require different decisions. For example, a reduction in an MDDI score during treatment supports a change in reported symptoms but does not by itself prove diagnostic remission or safe recovery from steroid-related complications. Combining patient-reported scores, clinical interviews, and real-world functioning gives a stronger account of progress.
What does research show about treatment?
Cognitive behavioral therapy adapted for BDD
Cognitive behavioral therapy (CBT) targeting BDD is the most established psychological treatment framework relevant to muscle dysmorphia. In a case formulation, treatment identifies appearance-based assumptions, attention to perceived flaws, repetitive checking and reassurance seeking, avoidance, and rigid rules that sustain distress. Behavioral experiments examine feared predictions in real situations. Exposure and response prevention (ERP) help the person approach avoided situations while reducing rituals that ordinarily provide brief relief. Work on body-image evaluation, broader identity, and meaningful activities can support this process. Treatment is collaborative, individualized, and adapted to medical risk and any co-occurring eating disorder or substance-use condition. NICE CG31.
Evidence is strongest for BDD as a broader diagnosis, not for muscularity-focused presentations alone. Systematic reviews of randomized controlled trials report improvements in BDD symptoms with cognitive and behavioral interventions, though trial designs, populations, active comparators, and follow-up lengths vary. Results for the full BDD population cannot be mechanically assigned to every person with muscle dysmorphia. Ko et al. (2026); Abdalla et al. (2026).
A recent muscle-dysmorphia-specific randomized trial
A 2025 open-label randomized study examined 59 male gym-goers with muscle dysmorphia and a history of anabolic-androgenic steroid or performance-enhancing drug use. Participants were assigned to 12 weeks of online CBT (30 people) or a waitlist (29 people). The investigators reported improvement on the MDDI and other self-report outcomes, including depressive symptoms, disordered eating, and problematic exercise. The reported within-treatment reduction in MDDI symptoms was large (d = 1.12), and gains were reported at three-month follow-up. This is direct but preliminary treatment evidence: the sample was small and specialized, the comparator was a waitlist rather than a credible active treatment, participants and assessors were not blinded, and follow-up was short. These features limit conclusions about comparative effectiveness and durability. The study supports further carefully designed trials rather than a universal promise of recovery from a fixed number of sessions. Çınaroğlu et al. (2025).
SSRIs and psychiatric treatment
Selective serotonin reuptake inhibitors (SSRIs) are among the evidence-supported medication options for clinically diagnosed BDD, with prescribing decisions based on symptom severity, co-occurring conditions, prior treatment, patient preferences, and safety. NICE recommends CBT including ERP for adults with mild BDD-related impairment; for moderate impairment, more intensive CBT or an SSRI; and for severe impairment, combined treatment. For adults with BDD, the guidance names fluoxetine as an initial medication, while explicitly noting that the use is off-label in that jurisdiction. Those recommendations come from BDD studies rather than a large medication trial specifically in muscle dysmorphia. Antidepressant treatment requires individualized monitoring, particularly early in treatment and around dose changes, for adverse effects, activation, worsening agitation, and suicidal thinking. Medication choice and adjustment belong to a qualified prescriber. NICE CG31.
Integrated care for eating, training, and drug-related risks
A muscle-dysmorphia treatment plan may need psychological therapy, medical evaluation, nutritional assessment, injury management, and substance-use care at the same time. Treatment of the appearance preoccupation should not ignore malnutrition, dangerous training despite injury, endocrine complications, or drug dependence. Likewise, focusing exclusively on gym behavior without addressing shame and compulsive appearance beliefs can leave the main source of suffering intact. Coordination between professionals is especially valuable when patients receive inconsistent advice from fitness culture, social media, and clinical services. The specific mix of interventions depends on a documented assessment rather than a generic program. Nagata et al. (2026); Çınaroğlu and Yılmazer (2025).
Adolescents and family-informed care
For young people with BDD, NICE recommends developmentally adapted CBT including ERP with appropriate family or caregiver involvement as first-line treatment. Families can help reduce repeated reassurance cycles while supporting ordinary activities and access to treatment. They should also attend to bullying, restrictive food practices, signs of unsafe supplement or steroid use, and excessive exercise despite injury. Decisions concerning medication for children and adolescents require specialist assessment and monitoring. The aim is to restore agency and functioning while treating the young person with dignity and preserving opportunities for safe, enjoyable movement. NICE CG31; Nagata et al. (2026).
Suicide risk, psychological distress, and clinical safety
Body dysmorphic disorder can be associated with severe depression and suicide risk. An individual presenting with muscle dysmorphia should therefore receive an appropriately direct, respectful assessment for suicidal ideation, self-harm, hopelessness, substance-related crises, and other urgent problems when clinically indicated. Researchers must not assume that population-level suicide estimates for BDD apply unchanged to every muscularity-focused subgroup, because muscle-specific risk data are limited. Nonetheless, safety planning and appropriate escalation are central parts of care when distress is severe. NICE CG31.
If someone expresses current intent to harm themselves, has a specific plan, experiences a serious medical complication, or cannot remain safe, urgent local emergency or crisis services and immediate professional evaluation are indicated. For less acute but persistent symptoms, seeking an assessment with a clinician experienced in BDD, eating disorders, and body-image concerns is an appropriate next step. This clinical article offers educational information and cannot determine any reader's diagnosis or individual treatment regimen.
Prevention and supportive environments
Prevention should address the mechanisms that can make one body ideal feel compulsory. Families, coaches, teachers, gyms, and clinicians can discuss training goals in terms of function, enjoyment, recovery, and health; identify bullying and appearance-based humiliation; support a wider range of valued identities; and encourage critical interpretation of highly curated or altered physique images. Honest discussion of anabolic drug use and its risks is more likely to support disclosure than stigmatizing language. Because controlled trials of muscle-dysmorphia-specific prevention programs are sparse, these proposals are better regarded as theoretically and clinically informed strategies than as proven ways to prevent the syndrome in every population. Nagata et al. (2026).
Exercise plans designed around flexibility, recovery, and realistic health goals can provide occasions to recognize a changing relationship to training. A warning sign is a shift from voluntary participation toward fear-driven necessity, especially if injury, illness, relationships, or school are repeatedly sacrificed. The appropriate response is supportive inquiry and professional assessment where necessary, not criticism of body shape or the automatic restriction of all physical activity. The practical goal is to restore informed choice and protect physical and psychological wellbeing.
Evidence quality and unresolved scientific questions
The strongest current conclusion is classificatory and clinical: muscularity-focused appearance preoccupation can meet BDD criteria, and comprehensive assessment should examine repetitive acts, impairment, and differential diagnoses. Evidence for BDD-focused CBT is established at the broader diagnostic level. Direct controlled treatment evidence in muscle dysmorphia remains preliminary, despite a promising recent randomized trial. Observational studies associate symptom severity with perfectionism, anxiety, compulsive traits, and anabolic steroid use; these associations are informative but are insufficient to establish causal direction. Mitchell et al. (2017); Çınaroğlu and Yılmazer (2025); Çınaroğlu et al. (2025).
Research priorities include representative population cohorts, longitudinal assessments beginning before the onset of symptoms, consistent clinical diagnostic interviews rather than questionnaire thresholds alone, measurement across sexes and genders, culturally validated instruments, and trials with active comparators and long-term follow-up. Investigators also need to distinguish the effects of competitive sport, social selection into particular activities, social media exposure, substance use, and preexisting psychiatric vulnerability. In a field with variable measures and sampling, the most responsible interpretation preserves these distinctions rather than presenting a single prevalence percentage as universal.
Frequently asked questions
Is muscle dysmorphia a mental disorder?
Muscle dysmorphia is a recognized specifier of body dysmorphic disorder in DSM-5-TR. The diagnosis depends on the full BDD criteria, including clinically significant distress or impairment and appropriate differential diagnosis. There is no separate DSM-5-TR disorder defined merely by wanting more muscle. DSM-related criteria.
Can a very muscular person experience muscle dysmorphia?
Yes. The central problem is perceived muscular inadequacy and its psychological and behavioral consequences, which may persist despite visible muscular development. Objective physique measurements cannot establish or exclude the condition. Nagata et al. (2026).
Is bodybuilding itself a sign of muscle dysmorphia?
No. Bodybuilding, training frequency, or physique competition is not a diagnostic criterion. An assessment examines appearance preoccupation, repetitive acts, distress, functional losses, other conditions, and medical risks. Higher average scale scores in selected bodybuilder samples do not identify an individual athlete as having BDD. Mitchell et al. (2017).
Does the MDDI score diagnose muscle dysmorphia?
No. The MDDI measures symptom dimensions and may support screening or progress monitoring. Clinical diagnosis requires a professional interview and context-sensitive assessment of BDD criteria. Compte et al. (2025).
Are muscle dysmorphia and eating disorders the same condition?
They can share concerns about body composition, food, and exercise, but their diagnostic criteria and central fears differ. A clinician assesses whether weight or fat preoccupation is accounted for by an eating disorder and whether multiple conditions require treatment. Nagata et al. (2026).
What treatment has the best evidence?
BDD-focused CBT including exposure and response prevention has the most established relevant psychological evidence. A small 2025 randomized study offers preliminary direct support for an adapted CBT program among male steroid users with muscle dysmorphia. SSRIs may be appropriate for diagnosed BDD under medical supervision, with their evidence largely extrapolated from broader BDD populations. NICE CG31; Çınaroğlu et al. (2025).
Related Articles
Body Dysmorphic Disorder: Symptoms, Diagnosis, and Treatment — the parent clinical overview of BDD criteria, assessment, and evidence-based care.
CBT for Body Dysmorphic Disorder: Evidence and Treatment Approaches — the established BDD-focused psychotherapy framework relevant to muscularity presentations.
Body Dysmorphic Disorder vs Body Dissatisfaction: What Is the Difference? — diagnostic thresholds and the relationship between dissatisfaction and clinical symptoms.
Internalizing Beauty Ideals: Thinness, Muscularity, and Appearance Pressure — sociocultural muscularity ideals and psychological internalization.
Body Dissatisfaction: Causes, Signs, and Psychological Effects — the broader non-diagnostic body-evaluation construct.
References
Abdalla, H., et al. (2026). The efficacy of cognitive behavioural therapy in the management of body dysmorphic disorder: A systematic review and meta-analysis. Clinical Psychology and Psychotherapy. https://doi.org/10.1002/cpp.70218.
Almeida, M., et al. (2026). Muscle dysmorphia among Brazilian gender-expansive individuals and transgender men: Factor structure and measurement invariance of the Muscle Dysmorphic Disorder Inventory (MDDI). Body Image, 58, 102168. https://doi.org/10.1016/j.bodyim.2026.102168.
American Psychiatric Association. (2023–2024). DSM-5-TR text updates, including obsessive-compulsive and related disorders. https://www.psychiatry.org/getmedia/2ed086b0-ec88-42ec-aa0e-f442e4af74e6/APADSM5TR-Update-September-2024.pdf.
Çınaroğlu, M., and Yılmazer, E. (2025). Muscle dysmorphia, obsessive–compulsive traits, and anabolic steroid use: A systematic review and meta-analysis. Behavioral Sciences, 15(9), 1206. https://doi.org/10.3390/bs15091206.
Çınaroğlu, M., Yılmazer, E., Ülker, S. V., and Sayar, G. H. (2025). Cognitive behavioral therapy for muscle dysmorphia and anabolic steroid-related psychopathology: A randomized controlled trial. Pharmaceuticals, 18(8), 1081. https://doi.org/10.3390/ph18081081.
Compte, E. J., Lopez, A., Kim, A. E., and Nagata, J. M. (2025). Muscle Dysmorphic Disorder Inventory (MDDI). In Handbook of Body Image-Related Measures. Cambridge University Press. https://www.cambridge.org/core/books/abs/handbook-of-body-imagerelated-measures/muscle-dysmorphic-disorder-inventory-mddi/29ED4557E139CDF7C1A138C689D7E853.
Hildebrandt, T., Langenbucher, J., and Schlundt, D. G. (2004). Muscularity concerns among men: Development of attitudinal and perceptual measures. Body Image, 1(2), 169–181. https://doi.org/10.1016/j.bodyim.2004.01.001.
Ko, Y.-C., Lee, C.-H., Wu, C.-S., and Huang, Y.-J. (2026). Efficacy and safety of cognitive and behavioral interventions in treating body dysmorphic disorder: A systematic review and meta-analysis of randomized controlled trials. General Hospital Psychiatry, 98, 41–49. https://doi.org/10.1016/j.genhosppsych.2025.11.013.
Mitchell, L., Murray, S. B., Cobley, S., Hackett, D., Gifford, J., Capling, L., and O'Connor, H. (2017). Muscle dysmorphia symptomatology and associated psychological features in bodybuilders and non-bodybuilder resistance trainers: A systematic review and meta-analysis. Sports Medicine, 47, 233–259. https://doi.org/10.1007/s40279-016-0564-3.
Nagata, J. M., Hur, J. O., Murakami, K., Ganson, K. T., He, J., Murray, S. B., and Lavender, J. M. (2026). Muscle dysmorphia in adolescents and young adults. Lancet Child and Adolescent Health, 10(2), 122–134. https://doi.org/10.1016/S2352-4642(25)00283-4.
National Institute for Health and Care Excellence (NICE). (2005; current online guidance). Obsessive-compulsive disorder and body dysmorphic disorder: Treatment (CG31). https://www.nice.org.uk/guidance/cg31/chapter/Recommendations.
Phillips, K. A., Hollander, E., Rasmussen, S. A., Aronowitz, B. R., DeCaria, C., and Goodman, W. K. (1997). A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale–Brown Obsessive Compulsive Scale. Psychopharmacology Bulletin, 33(1), 17–22. https://pubmed.ncbi.nlm.nih.gov/9133747/.
Rhea, D. J., Lantz, C. D., and Cornelius, A. E. (2004). Development of the Muscle Dysmorphia Inventory (MDI). Journal of Sports Medicine and Physical Fitness, 44(4), 428–435. https://pubmed.ncbi.nlm.nih.gov/15758857/.